TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oncology Institute ( (TOI) ) has shared an announcement.
On December 1, 2025, The Oncology Institute announced the resignation of Gabe Ling from its Board of Directors, effective the same day. The resignation is not due to any disagreements with the company. A search for new independent directors with expertise in healthcare and value-based care has been initiated to enhance the board’s capabilities and support the company’s mission and growth goals.
The most recent analyst rating on (TOI) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Oncology Institute stock, see the TOI Stock Forecast page.
Spark’s Take on TOI Stock
According to Spark, TipRanks’ AI Analyst, TOI is a Neutral.
The Oncology Institute’s stock score is primarily impacted by its financial instability and poor valuation metrics. While the earnings call provided some optimism with revenue growth and strategic advancements, the technical analysis indicates bearish momentum. The company’s financial health remains a significant concern, overshadowing the positive developments.
To see Spark’s full report on TOI stock, click here.
More about Oncology Institute
The Oncology Institute (NASDAQ: TOI), founded in 2007, is a leading value-based oncology group in the United States, providing specialized cancer care to approximately 1.9 million patients. The company operates over 100 clinics and affiliate locations across five states, offering services such as clinical trials and transfusions.
Average Trading Volume: 2,261,600
Technical Sentiment Signal: Buy
Current Market Cap: $308.9M
See more insights into TOI stock on TipRanks’ Stock Analysis page.